Treatment (osimertinib) for Non-Small Cell Lung Cancer
This trialstudies a drug to help stop the growth of advanced or recurring non-small cell lung cancer with an EGFR mutation.
- Non-Small Cell Lung Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
1 Primary · 3 Secondary · Reporting Duration: Up to 5 years
Side Effects for
1 Treatment Group
1 of 1
20 Total Participants · 1 Treatment Group
Primary Treatment: Treatment (osimertinib) · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there vacancies left in this clinical experiment for participants?
"Affirmative. Clinicaltrials.gov's records show that recruitment for this research is ongoing, beginning with it's initial post on April 5th 2018 and most recently updated on December 10th 2022. The investigation requires 20 people to be recruited from 100 medical facilities." - Anonymous Online Contributor
How extensive is the current participant pool for this clinical trial?
"20 participants, who satisfy the necessary requirements, are needed to complete this trial. People can join from two sites: Illinois CancerCare - Washington in Washington, Iowa or Illinois CancerCare-Dixon in Dixon, Kansas." - Anonymous Online Contributor
Is this an unprecedented research project?
"Currently, 102 trials are underway for osimertinib in 1061 cities across 51 nations. This medication's evaluation and testing first began in 2013 under the auspices of AstraZeneca with 603 participants. From this point up until now, 31 such studies have been successfully concluded." - Anonymous Online Contributor
Has the FDA certified osimertinib for therapeutic use?
"The safety rating of osimertinib is a 2 due to limited evidence in Phase 2 trials that suggests relative security, however there are no results yet indicating its efficacy." - Anonymous Online Contributor
Could you please provide a synopsis of the past research done related to osimertinib?
"Currently, there are 102 studies regarding osimertinib in progress with 17 of those trials having reached Phase 3. Most of these investigations into this treatment occur at the Uniondale site; however, 5,031 locations worldwide run clinical experiments for osimertinib." - Anonymous Online Contributor
In which sites can this clinical experiment be accessed?
"A multitude of facilities are on-board to facilitate this medical trial, such as Illinois CancerCare - Washington in Washington, Iowa; Illinois CancerCare-Dixon in Dixon, Kansas; and Jennie Edmundson Memorial Hospital in Council Bluffs, Michigan." - Anonymous Online Contributor